{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:27:53Z","timestamp":1790036873547,"version":"4.0.1"},"reference-count":64,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Hodgkin Lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) is a B\u2010cell lymphoproliferative disorder with an excellent prognosis for the majority of patients who are treated with multi\u2010agent chemotherapy, with or without radiation. A subset of patient, however, does not respond to therapy or relapses after accomplishing an initial response. Their outcome is poor and new treatment strategies are urgently needed for this patient population. Recent advances in the understanding of the tumour biology of <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> and its microenvironment have ushered a new era of targeted\u2010 and immuno\u2010therapies with remarkable activity. Most notably, the antibody\u2010drug conjugate brentuximab\u2010vedotin, and the immune checkpoint blockers pembrolizumab and nivolumab have recently been approved by the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> Food and Drug Administration and have transformed the therapeutic landscape of this disease. Other novel drug compounds are being investigated either as single agents or in combination and hold promise to further the field.<\/jats:p>","DOI":"10.1111\/bjh.15695","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T12:17:22Z","timestamp":1544530642000},"page":"105-112","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Novel therapeutic agents for relapsed classical Hodgkin lymphoma"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7254-5374","authenticated-orcid":false,"given":"Gottfried","family":"von Keudell","sequence":"first","affiliation":[{"name":"Lymphoma Service Memorial Sloan\u2010Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Lymphoma Service Memorial Sloan\u2010Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4314"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.009"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704621"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11828"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.12.2342"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.222"},{"key":"e_1_2_11_8_1","first-page":"214892","article-title":"A phase 1 study investigating the combination of AFM13 and pembrolizumab in patients with relapsed\/refractory Hodgkin Lymphoma after brentuximab vedotin failure: updated safety and efficacy data","volume":"2018","author":"Bartlett N.L.","year":"2018","journal-title":"EHA Learning Center"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.187"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0059"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1194"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_54"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","unstructured":"Chen R. Gibb A.L. Collins G.P. Popat R. El\u2010Sharkawi D. Burton C. Lewis D. Miall F. Forgie A. Compagnoni A. Andreola G. Brar S. Thall A. Woolfson A.&Radford J.(2017b)Blockade of the PD\u20101 checkpoint with anti\u2013PD\u2010L1 avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (cHL). In:14th International Conference on Malignant Lymphoma June 14\u201017 2017 Lugano Switzerland. Abstract No. 055","DOI":"10.1002\/hon.2437_54"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.011"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1725"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-362475"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.572"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05881.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx028"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"e_1_2_11_24_1","first-page":"1510","article-title":"Interim results from a phase 1 study of ADCT\u2010301 (Camidanlumab Tesirine) show promising activity of a novel pyrrolobenzodiazepine\u2010based antibody drug conjugate in relapsed\/refractory Hodgkin\/non\u2010Hodgkin lymphoma","volume":"130","author":"Horwitz S.M.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-018-0103-z"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1820.1820"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-288373"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275305"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.08.014"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.534"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386763"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V128.22.1107.1107","article-title":"Pembrolizumab in relapsed\/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 Keynote\u2010087 study","volume":"128","author":"Moskowitz C.H.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-772632"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66659-7"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06759.x"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703891"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-812701"},{"key":"e_1_2_11_44_1","first-page":"214507","article-title":"Checkmate 205 cohort D: a phase 2 trial of nivolumab for newly diagnosed advanced\u2010stage classical Hodgkin Lymphoma","volume":"2018","author":"Ramchandren R.","year":"2018","journal-title":"EHA Learning Center"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI94306"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.55.013"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0201"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3994"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21166"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8401"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.2415"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1365"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70265-0"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5223"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.1350"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.205"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15695","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T12:07:11Z","timestamp":1694606831000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,11]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/bjh.15695"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15695","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,11]]},"assertion":[{"value":"2018-12-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}